Skip to main content

Table 1 Changes of mRNA expression in BJAB, OCI-LY3 and SU-DHL-6 cells after incubation with the c-MYC-inhibitor (5 µM), LY294002 (5 µM), Rapamycin (500 nM), PD98059 (10 µM) and SB203580 (10 µM) for 24 h

From: Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability

  GLUT1 HK2 G6Ptase LDHA
BJAB cells
c-MYC-inh.
ΔΔCT 1.71 ± 0.11 ↓ −0.45 ± 0.16 ↑ −1.69 ± 0.14 ↑ 1.09 ± 0.14 ↓
Fold of untreated 0.31 (0.28–0.33)* 1.37 (1.22–1.53)* 3.23 (2.93–3.56)* 0.47 (0.43–0.52)*
LY294002
ΔΔCT 0.03 ± 0.10 0.08 ± 0.09 −0.41 ± 0.10 ↑ 1.24 ± 0.17 ↓
Fold of untreated 0.98 (0.91–1.06) 0.95 (0.89–1.01) 1.33 (1.24–1.42)* 0.42 (0.38–0.48)*
Rapamycin
ΔΔCT 0.78 ± 0.09 ↓ 0.84 ± 0.08 ↓ −0.72 ± 0.17 ↑ 1.33 ± 0.14 ↓
Fold of untreated 0.58 (0.55–0.62)* 0.56 (0.53–0.59)* 1.65 (1.46–1.85)* 0.40 (0.36–0.44)*
PD98059
ΔΔCT −0.02 ± 0.13 0.01 ± 0.10 −0.45 ± 0.09 ↑ 0.04 ± 0.10
Fold of untreated 1.01 (0.93–1.11) 0.99 (0.93–1.06) 1.37 (1.28–1.45)* 0.97 (0.91–1.04)
SB203580
ΔΔCT 0.01 ± 0.08 −0.02 ± 0.07 0.05 ± 0.11 −0.09 ± 0.12
Fold of untreated 0.99 (0.94–1.05) 1.01 (0.97–1.06) 0.97 (0.90–1.04) 1.06 (0.98–1.16)
OCI-LY3 cells
c-MYC-inh.
ΔΔCT 1.12 ± 0.14 ↓ −0.43 ± 0.12 ↑ −1.23 ± 0.17 ↑ 0.78 ± 0.12 ↓
Fold of untreated 0.46 (0.42–0.51)* 1.35 (1.24–1.46)* 2.35 (2.08–2.64)* 0.58 (0.54–0.63)*
LY294002
ΔΔCT 0.13 ± 0.15 −0.04 ± 0.10 −0.60 ± 0.10 ↑ 1.03 ± 0.14 ↓
Fold of untreated 0.91 (0.82–1.01) 1.03 (0.96–1.10) 1.52 (1.41–1.62)* 0.49 (0.44–0.54)*
Rapamycin
ΔΔCT 0.49 ± 0.13 ↓ 0.98 ± 0.15 ↓ −0.97 ± 0.10 ↑ 1.56 ± 0.20 ↓
Fold of untreated 0.71 (0.65–0.78)* 0.51 (0.46–0.56)* 1.96 (1.83–2.10)* 0.34 (0.30–0.39)*
PD98059
ΔΔCT −0.03 ± 0.18 0.01 ± 0.13 −0.03 ± 0.08 0.01 ± 0.16
Fold of untreated 1.02 (0.90–1.16) 0.99 (0.91–1.09) 1.02 (0.97–1.08) 0.99 (0.89–1.11)
SB203580
ΔΔCT 0.16 ± 0.14 0.44 ± 0.12 ↓ −0.08 ± 0.13 −0.03 ± 0.08
Fold of untreated 0.90 (0.81–0.99) 0.74 (0.68–0.80)* 1.06 (0.97–1.16) 1.02 (0.97–1.08)
SU-DHL-6 cells
c-MYC-inh.
ΔΔCT 1.23 ± 0.12 ↓ −0.36 ± 0.07 ↑ −0.93 ± 0.12 ↑ 1.19 ± 0.08 ↓
Fold of untreated 0.43 (0.39–0.46)* 1.28 (1.22–1.35)* 1.91 (1.75–2.07)* 0.44 (0.41–0.46)*
LY294002
ΔΔCT −0.11 ± 0.11 −0.05 ± 0.14 0.51 ± 0.08 ↑ 0.98 ± 0.11 ↓
Fold of untreated 1.08 (1.00–1.16) 1.04 (0.94–1.14) 1.42 (1.35–1.51)* 0.51 (0.47–0.55)*
Rapamycin
ΔΔCT 0.66 ± 0.09 ↓ −0.83 ± 0.16 ↓ −0.82 ± 0.16 ↑ 0.85 ± 0.09 ↓
Fold of untreated 0.63 (0.59–0.67)* 0.56 (0.50–0.63)* 1.77 (1.58–1.97)* 0.55 (0.52–0.59)*
PD98059
ΔΔCT 0.04 ± 0.16 0.09 ± 0.11 −0.05 ± 0.13 0.30 ± 0.10 ↓
Fold of untreated 0.97 (0.87–1.09) 0.94 (0.87–1.01) 1.04 (0.95–1.13) 0.81 (0.76–0.87)*
SB203580
ΔΔCT −0.08 ± 0.15 0.05 ± 0.09 0.14 ± 0.14 0.17 ± 0.17
Fold of untreated 1.06 (0.95–1.17) 0.97 (0.91–1.03) 0.91 (0.82–1.00) 0.89 (0.79–1.00)
  1. ΔΔCT values referred to changes of mRNA levels corrected to expression of HPRT1 mRNA; changes of expression values represent percent of control, mean ± standard deviation from threefold determinations
  2. * and arrows indicate significant changes (p < 0.05, Mann–Whitney test)